Cemdisiran for Myasthenia Gravis: Improves Daily Life
Summary of Regeneron’s NIMBLE Trial Results for Myasthenia Gravis (gMG) Treatment
This article details the results of the NIMBLE trial investigating cemdisiran (a siRNA reducing C5 levels) and pozelimab (Veopoz, a C5 complement inhibitor) for the treatment of generalized Myasthenia Gravis (gMG). here’s a breakdown of the key findings:
Key Findings:
Cemdisiran Monotherapy Superior: Cemdisiran alone demonstrated superior improvements in gMG-specific outcomes compared to the combination of cemdisiran and pozelimab (“cemdi-poze”).
Meaningful Improvements in Daily Function: Both cemdisiran monotherapy and cemdi-poze improved quality of life as measured by the MG-ADL total score at week 24, compared to baseline.
Strong Complement Inhibition: Both regimens effectively inhibited complement activity, with cemdisiran alone achieving 74% inhibition and cemdi-poze reaching nearly 99% inhibition. This is critically important as C5 activation disrupts nerve-muscle communication in gMG.
Convenient Dosing: Cemdisiran offers a convenient quarterly (every 12 weeks) subcutaneous governance.
Trial Details (NIMBLE Trial):
Participants: Adults with symptomatic gMG who tested positive for anti-AChR antibodies (and possibly receiving standard immunosuppressants).
Randomization: Participants were randomized to receive:
Cemdisiran 600mg every 12 weeks
Cemdi-poze (cemdisiran 200mg + pozelimab 200mg) every 4 weeks
Placebo every 4 weeks
Key Measurements:
MG-ADL: Patient-reported questionnaire assessing daily functions (talking, eating, vision, breathing, mobility). Primary endpoint.
QMG: Physician-administered assessment of vision, speaking/swallowing, breathing, and limb function. Key secondary endpoint.
Results Comparison (Placebo-Adjusted):
| Outcome Measure | Cemdisiran | cemdi-Poze |
|—|—|—|
| MG-ADL Change from Baseline | -2.30 | -1.74 |
| QMG Change from Baseline | -2.77 | -1.86 |
Mean Change from Baseline:
| Outcome Measure | Cemdisiran | Cemdi-Poze |
|—|—|—|
| MG-ADL Change from Baseline | -4.52 | -3.96 |
| QMG Change from Baseline | -4.24 | -3.32 |
Regeneron’s Perspective:
Regeneron believes cemdisiran has the potential to be a “best-in-class” treatment for gMG, offering robust efficacy with a convenient dosing schedule and potentially a more favorable safety profile due to less complete complement blockade.
Source: News release from Regeneron.